A Randomized, Double-Blinded, Adaptive Phase 2 Study to Evaluate the Safety and Efficacy of IV or IV/PO Omadacycline and IV/PO Levofloxacin in the Treatment of Adults With Acute Pyelonephritis
Phase of Trial: Phase II
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs Omadacycline (Primary) ; Omadacycline (Primary) ; Levofloxacin; Levofloxacin
- Indications Pyelonephritis
- Focus Therapeutic Use
- Sponsors Paratek Pharmaceuticals
- 08 Nov 2019 Status changed from active, no longer recruiting to completed.
- 31 Oct 2019 Status changed from recruiting to active, no longer recruiting, according to a Paratek Pharmaceuticals media release.
- 31 Oct 2019 According to a Paratek Pharmaceuticals media release, additional analyses are ongoing and the company plans on presenting data from the study at a future medical conference.